References
- Williams M. Purine receptors in mammalian tissues: pharmacology and functional significance. Ann. Rev. Pharmacol. Toxicol. 1987; 27: 315–345
- Linden J. Structure and function of A1 adenosine receptors. FASEB J. 1991; 5: 2668–2676
- Daly J. W. Adenosine receptors: targets for future drugs. J. Med. Chem. 1982; 25: 197–207
- Van Calker D., Muller M., Hamprecht B. Adenosine regulates via t w o different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 1979; 33: 999–1005
- Blazynski C., Cohen A I., Früh B., Niemeyer G. Adenosine : autoradiographic localization and electrophysiologic effects in the cat retina. Invest. Ophthalmol. Vis Sci. 1989; 30: 2533–2536
- Braunagel S. C., Xiao J G., Chiou G. C.Y. The potential role of adenosine in regulating blood flow in the eye. J. Ocul. Pharmacol. 1988; 4: 61–73
- Hasslinger C. Catapres (2- [2 6-dichlorophenylaminol-2- imidazoline hydrochloride)- a new drug lowering intraocular pressure. Klin. Mbl Augenheilk. 1969; 154: 95–105
- Mekki Q. A., Hassan S. M., Turner P. Bromocriptine lowers intraocular pressure without affecting blood pressure. Lancet 1983; 1: 1250–1255
- Burke J. A., Potter D. E. Ocular effects of a relatively selective α2 agonist (UK-14,304) in cats, rabbits and monkeys. Curr. Eye Res 1986; 5: 665–676
- Crosson C. E., Burke J A., Chan M. F., Potter D. E. Prejunctional adrenoceptor activity of N-0437: a relatively selective DA2 dopamine receptor agonist. Eur. J. Pharmacol. 1990; 178: 351–355
- Mittag T. W., Tormay A. Drug responses of adenylate cyclase in iris-ciliary body determined by. adenine labeling. Invest. Ophthalmol. Vis. Sci. 1985; 26: 396–399
- Snyder S. H. Adenosine as a neuromodulator. Ann. Rev. Neurosci. 1985; 8: 103–124
- Fredholm B. B., Dunwiddie T. V. How does adenosine inhibit transmitter release?. Trends Pharmacol. Sci. 1988; 7: 180–185
- Londos C., Wolff J., Cooper D. M.F. Adenosine as a regulator of adenylate cyclase. “Purinergic Receptors,”, G. Burnstock. Receptors and Recognition Series. B, Chapman and Hall, London/New York 1981; vol. 12: 2287–2323
- Häggblad J., Fredholm B. B. Adenosine and neuropeptide Y enhance α1-adrenoceptor-induced accumulation of inositol phosphates and attenuate forskolin-induced accumulation of cyclic AMP in rat vas deferens. Neurosci. Lett. 1987; 82: 211–216
- Linden J., Delahunty T. M. Receptors which inhibit phosphoinositide breakdown. TIPS 1989; 10: 114–120
- Schimmel R. J., Elliot M. E. Adenosine inhibits phenylephrine activation of phospholipase A2 in hamster brown adipocytes. Biochem. Biophys. Res. Commun. 1988; 152: 886–892
- Martin J. V., Berman K. F., Skolnick P., Mendelson W. B. Behavioral and electroencephalographic effects of the adenosine A1 agonist L- PIA. Pharmacol. Biochem. Behav. 1989; 34: 507–510
- Spielman W. S., Arend L. J. Adenosine receptors and signaling in the kidney. Hypertension 1991; 17: 117–130
- Belardinelli L., Linden J., Berne R. M. The cardiac effects of adenosine. Prog. Cardiovasc. Dis. 1989; 32: 73–97
- Bruns R. F., Lu G. H., Pugsley T. A. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mnl. Pharmacol. 1986; 29: 331–346
- Rowland J. M., Potter D. E. Adrenergic drugs and intraocular pressure: hypertensive effects of epinephrine. Ophthal. Res. 1980; 12: 221–229
- Potter D. E., Nicholson H. T., Rowland J. M. Ocular hypertensive response to β-adrenoceptor agonists. Curr. Eye Res. 1982; 2: 711–719
- Wang R. F., Camras C. B., Lee P. Y., Podos S. M., Bito L. Z. Effects of prostaglandins F2ar Ez, and their esters in glaucomatous monkey eyes. Invest. Ophthalmol. Vis. Sci. 1990; 31: 2466–2470